Connect to other sites within the UBM Medica Network
It has long been understood that MI may increase the risk of atrial fibrillation. A study in JAMA-Internal Medicine now finds that that the opposite relationship may also be true.
Ablation vs Medication: Which First for Atrial Fibrillation and for Who?
A small study provides good evidence that radiofrequency ablation as first-line therapy has a lower failure rate vis a vis recurrence of AF when compared with antiarrhythmic therapy. But, there is more to this story.
NSAID Use Increases Risk of Atrial Arrhythmias
According to a study published in the British Medical Journal, the risk of atrial fibrillation/atrial flutter is greater in NSAID-naive patients than in those with previous exposure.
2014 Atrial Fibrillation Management Guidelines Released
Four updates to the guidelines are important for primary care physicians to review.
Genotype-Guided Warfarin Dosing: Does It Improve TTR?
In clinical scenarios where warfarin is still the drug of choice for anticoagulation, it is still a challenge to achieve optimal time in therapeutic range. Is there promise in a new dosing paradigm?
Complex LAA Shape Predicts Thromboembolic Risk
Results of a new study suggest that number of LAA lobes may one day be useful as an element of the CHADS2 scoring system for embolic risk in patients with atrial fibrillation.
RE-LY AF Registry: Hypertension Most Common Risk Factor Worldwide
Comprising 15,400 patients from 46 countries, the RE-LY AF registry offers a notable opportunity to study variations in presentation of atrial fibrillation and its risk factors.
In Dialysis Patients With Atrial Fibrillation, Anticoagulation Offers No Benefit
In dialysis patients, anticoagulation for AF may be cause for clinical equipoise, regardless of bleeding risk score. New research, reported here, may begin to shift the balance.
Women and Heart Disease: Incidence, Prevalence, Progress, and the Future
Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women
The Great Beta-Blocker Debate: The Pros and Cons
Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.
AHA 2012 Highlights: Multivitamins, Omega-3s, the Polypill, and More
Platelet function monitoring and adjustment of treatment based on results after coronary stenting does not improve clinical outcomes . . . and other findings from the AHA Scientific Sessions.
Who Needs Beta-Blockers? Analysis Raises Questions
A new analysis of data from a large international registry finds that use of beta-blockers in patients with and without a history of coronary artery disease does not reduce cardiovascular events.